Gene Therapy for Primary and Metastatic Cancer to the Liver
作者： M. Wayne Flye , Katherine Parker Ponder
DOI: 10.1007/978-1-4471-1506-9_13
关键词:
摘要: The term ‘gene therapy’ applies to all approaches involving the introduction of genetic material into a patient’s cells produce therapeutic protein or inhibit gene function. This therapy is possible because viruses, bacteria, plants and mammals share same interchangeable code. Gene currently being employed in an attempt cure ameliorate growth various malignancies.1,2 potential experimental therapies used for treating cancer may (1) transfer ‘suicide genes’ whose products converts non-toxic precursor toxic molecule that kills (2) regulate oncogenes (3) tumour suppressor genes, such as p53 (4) promote reinforce immunological response (5) proteins necessary promoting metastases (6) angiogenesis (7) drug resistance genes bonemarrow protection from high-dose chemotherapy. area its infancy most have yet pass even preliminary clinical tests demonstrating their overall safety efficacy. Common issues are applied diseases involves transfer, regulation, vector efficiency safety.
springer.com
sci-hub.st 参考文章(68)
Wills Kn, Harris Mp, Gregory Rj, Huang Wm, Machemer T, Maneval Dc, Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Therapy. ,vol. 2, pp. 191- ,(1995)
SC Kennedy, MW Flye, KP Ponder, DG Hafenrichter, X Wu, SD Rettinger, Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes Blood. ,vol. 84, pp. 3394- 3404 ,(1994) , 10.1182/BLOOD.V84.10.3394.3394
B. Sorrentino, T. Velu, S. Russell, Malcolm Brenner, T. Blankenstein, O. Cohen-Haguenauer, B. Gansbacher, M. Blaese, Vectors in cancer therapy: how will they deliver? Cancer Gene Therapy. ,vol. 2, pp. 291- 297 ,(1995)
M. Wayne Flye, Elizabeth M. Brunt, William Bowling, Katherine Parker Ponder, Daniel G. Hafenrichter, Susan C. Kennedy, Yue-Zhen Lin, Ras-transduced Diethylnitrosamine-treated Hepatocytes Develop into Cancers of Mixed Phenotype in Vivo Cancer Research. ,vol. 55, pp. 5242- 5250 ,(1995)
M S Greenblatt, W P Bennett, M Hollstein, C C Harris, Mutations in the p53 Tumor Suppressor Gene: Clues to Cancer Etiology and Molecular Pathogenesis Cancer Research. ,vol. 54, pp. 4855- 4878 ,(1994)
Taiki Tamaoki, Hidekazu Nakabayashi, Toshi Kotani, Gary McGarrity, Paul Hallenbeck, W. French Anderson, Shuichi Kaneko, Yawen L. Chiang, Adenovirus-mediated Gene Therapy of Hepatocellular Carcinoma Using Cancer-specific Gene Expression Cancer Research. ,vol. 55, pp. 5283- 5287 ,(1995)
Shiratori Y, Omata M, Tamaoki T, Wakimoto H, Kanai F, Tanaka T, Ohashi M, Lan Kh, Hamada H, Nakabayashi H, Okudaira T, Yoshida Y, In Vivo Gene Therapy for α-Fetoprotein-producing Hepatocellular Carcinoma by Adenovirus-mediated Transfer of Cytosine Deaminase Gene Cancer Research. ,vol. 57, pp. 461- 465 ,(1997)
M Fukayama, R Kikuchi-Yanoshita, Y Maeda, M Seki, M Konishi, T Mori, M Koike, H Iino, K Tanaka, S Ito, Genetic Changes of Both p53 Alleles Associated with the Conversion from Colorectal Adenoma to Early Carcinoma in Familial Adenomatous Polyposis and Non-Familial Adenomatous Polyposis Patients Cancer Research. ,vol. 52, pp. 3965- 3971 ,(1992)
Cynthia A. Richards, Brian E. Huber, Vincent C. Knick, Elizabeth A. Austin, Steven S. Good, Stephen Tibbels, In Vivo Antitumor Activity of 5-Fluorocytosine on Human Colorectal Carcinoma Cells Genetically Modified to Express Cytosine Deaminase Cancer Research. ,vol. 53, pp. 4619- 4626 ,(1993)
C Fleischacker, S Gamble, K L Rock, Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. Journal of Immunology. ,vol. 150, pp. 1244- 1252 ,(1993)